Similarities And Differences Between The CTA And IND
Source: Veristat, Inc.
Deciding to submit a Clinical Trial Authorisation (CTA) or Investigational New Drug Application (IND) is a significant milestone in developing a new drug, biologic, or vaccine.
Suppose the goal of a development program is to initiate clinical trials within European member states, the United Kingdom, or North America. In that case, strategic consideration to how, when, and whether to submit a CTA or IND is critically important.
Consider the purpose, content, and procedural similarities and differences between the CTA and IND.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Veristat, Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more